December 6, 2006 -- Artes Medical of San Diego is in the line-up to make its IPO next week. The company is in an interesting position: the FDA recently approved ArteFill, its injectable aesthetic inplant product that corrects smile-lines, but will not begin marketing the product until early next year. ArteFill differs from its competitors in that Artes takes the commonly used ingredient of bovine-derived collagen and adds an ingredient to make the injection non-resorbable, thereby lengthening the effect. We look at ArteFill, at Artes, and at its finances...
